Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

Item
http://www.wikidata.org/entity/Q30446914
Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule ProbesDiscovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375)Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses.Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditionsDesign of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsActivation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophreniaDiverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.Discovery of novel N-substituted oxindoles as selective m1 and m4 muscarinic acetylcholine receptors partial agonists.Spirocyclic replacements for the isatin in the highly selective, muscarinic M1 PAM ML137: the continued optimization of an MLPCN probe molecule.Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetrationPrefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256.Involvement of neurotransmitters in the action of the nociceptin/orphanin FQ peptide-receptor system on passive avoidance learning in rats.
P2860

Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

Item
http://www.wikidata.org/entity/Q30446914
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting selective activation ...... ve allosteric modulator ML169.
@ast
Targeting selective activation ...... ve allosteric modulator ML169.
@en
type
label
Targeting selective activation ...... ve allosteric modulator ML169.
@ast
Targeting selective activation ...... ve allosteric modulator ML169.
@en
prefLabel
Targeting selective activation ...... ve allosteric modulator ML169.
@ast
Targeting selective activation ...... ve allosteric modulator ML169.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Targeting selective activation ...... ve allosteric modulator ML169.
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932